Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Clinical Case Reports|October 6, 2023
Protracted complete response after limited checkpoint inhibitor dosing: A case reportQuinne Sember, Darren SigalCurrent Oncology Reports|February 5, 2019
TRK Inhibitors: Clinical Development of LarotrectinibMunveer S Bhangoo, Darren SigalJournal of Personalized Medicine|January 19, 2019
The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal CancerDavid J Hermel, Darren SigalLeukemia & Lymphoma|October 10, 2009
Cladribine in the treatment of hairy cell leukemia: initial and subsequent resultsEdward Huynh, Darren Sigal, Alan SavenCancer Medicine|December 8, 2022
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patientsGregory P Botta, Tridu R Huynh, Samantha R Spierling-Bagsic, et al.Cancer Medicine|March 14, 2023
Do patients with metastatic pancreatic adenocarcinoma to the lung have improved survival?Aren Ebrahimi, Jason Cham, Leah Puglisi, et al.Frontiers in Oncology|July 8, 2025
CD16 and Siglec expression refine the phenotypic heterogeneity of steady-state myeloid-derived suppressor cellsChris D St Laurent, Zeinab Jame-Chenarboo, Alyssa E Beck, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine CancerDarren Sigal, Marie Tartar, Marin Xavier, et al.The Oncologist|July 2, 2026
Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3Apostolia Maria Tsimberidou, Claire Verschraegen, Darren Sigal, et al.Cancer Chemotherapy and Pharmacology|September 23, 2024
Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumorsApostolia Maria Tsimberidou, Axel Grothey, Darren Sigal, et al.Pageof 2